These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 29326490)
1. Investigation of K Pinjari MJS; Somani R; Gilhotra RM Indian J Pharmacol; 2017; 49(4):297-303. PubMed ID: 29326490 [TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Kamath AV; Wang J; Lee FY; Marathe PH Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625 [TBL] [Abstract][Full Text] [Related]
3. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456 [TBL] [Abstract][Full Text] [Related]
4. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Kamath AV; Chong S; Chang M; Marathe PH Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193 [TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240 [TBL] [Abstract][Full Text] [Related]
7. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144 [TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study. Bera R; Kundu A; Sen T; Adhikari D; Karmakar S Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641 [TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
11. Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction. Jana S; Rastogi H Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):781-791. PubMed ID: 28070878 [TBL] [Abstract][Full Text] [Related]
12. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329 [TBL] [Abstract][Full Text] [Related]
13. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis. Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685 [TBL] [Abstract][Full Text] [Related]
14. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472 [TBL] [Abstract][Full Text] [Related]
15. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Varma MV; Panchagnula R Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503 [TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720 [TBL] [Abstract][Full Text] [Related]
17. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound. S S; Vuppu S J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460 [TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600 [TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245 [TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]